Skip to content
Reflections of yellow marbles on metal holders
Reflections of yellow marbles on metal holders

Life Sciences

Our global Life Sciences practice comprises a multi-disciplinary team. We act for companies and their investors across the industry, including in the pharmaceuticals, biotech, veterinary, medtech, diagnostics and healthcare sectors.

The practice operates on a cross-border basis and covers the full spectrum of legal support. We advise on mergers and acquisitions, commercial transactions (including licensing and collaborations), IP (both contentious and non-contentious), capital markets and finance, regulatory and dispute resolution. Our international network ensures that we have a ready resource of expertise in a number of jurisdictions, including those in emerging markets, and that we are well positioned to advise on cross-border work.

We have won a reputation for providing far-sighted advice to some of the world’s leading life science companies – including GlaxoSmithKline, Pfizer, UCB, Merck, Bayer and Novartis.

News & insights

A person holding a test tube containing cannabis leaves

Publications: 29 NOVEMBER 2019

Flying high

As more countries liberalise their cannabis policies, there has been a rapid increase in the number of registered IP rights as competitors seek to establish their places in the market.

Read more

Publications: 04 OCTOBER 2019

Outstanding performance by A&O in global M&A league tables

A&O has marked the end of Q3 2019 with an outstanding performance in the M&A league tables; the result of advising on a number of complex, high-value transactions in a wide range of sectors and markets, around our global network in 2019.

Read more

Publications: 28 AUGUST 2019

NICE consults on Draft Guideline on prescribing medicinal cannabis

On 8 August 2019, the National Institute for Health and Care Excellence (NICE)1 published a draft guideline on prescribing cannabis-based medicinal products (the Draft Guideline) for consultation.2

Read more
China removes barriers

Publications: 26 JULY 2019

China removes more barriers to market entry

The pledge by President Xi at the G20 Summit in Osaka that China would continue to liberalise market access has seen immediate progress in the form of a new update to the Catalogue of Encouraged Industries for Foreign Investment (the Industries Catalogue) and the publication of two revised negative lists governing foreign investment.

Read more

Recognition

Related links

Life Sciences Hub

We report on EU and national regulatory, compliance, intellectual property and transactional developments in the sector.

View the blog

CRISPR microsite

The characterisation and optimisation of the CRISPR (also known as CRISPR-Cas) system for gene editing and other applications, is undoubtedly one of the most powerful and ground breaking advances in the history of biotechnology.

Go to microsite

Growth Capital microsite

Allen & Overy is an engaged and active player in the growth company ecosystem.

Go to microsite

Cannabis microsite

According to UN estimates, the global cannabis market is currently worth approximately USD150 billion annually. 

Go to microsite

Download our sector brochure

Life sciences A&O red molecules

An insight in to our Life Science and Healthcare sector 2019

Our global Life Sciences and Healthcare sector comprises a multi-disciplinary team. We act for companies and their investors across the industry, including in the pharmaceuticals, biotech, animal health, consumer health, med tech, and diagnostics sectors.

Related content

Global trends in merger control enforcement

Record levels in the first half of 2018 and considerable contraction in the second.